In February 2015, Palbociclib in combination with letrozole was accepted for accelerated approval by the FDA for the treatment of ER+, HER2− advanced breast cancer as initial endocrine-based therapy in postmenopausal women. This evidence concerns the gene ESR1 and breast carcinoma.